Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495664 | 0.87 | HTT (0.68) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL15174092 | 0.87 | HTT (0.63) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL1322947 | 0.85 | MAPT (0.61) | MAPK1MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4380651 | 0.84 | HTT (0.64) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| Hydrochloric Acid SCHEMBL8882875 | 0.84 | HTT (0.63) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL2845183 | 0.83 | HTT (0.67) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL2848243 | 0.83 | HTT (0.67) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL6331262 | 0.83 | HTT (0.67) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL5685418 | 0.83 | HTT (0.58) | HTTLMNAMAPK1RAB9ATAS1R3 | |
| SCHEMBL4029594 | 0.83 | HTT (0.58) | HTTLMNAMAPK1RAB9ATAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9879007-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2017-05-11 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885LMNA 178/4885MAPK1 3878/4885 |
| US-20180105526-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885LMNA 178/4885MAPK1 3878/4885 |
| US-20170129885-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | HTT 264/4885LMNA 178/4885MAPK1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.